Oncovista Innovative Therapies IncOver The Counter Market:OVIT
- LAST PRICE0.0001
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0001
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Oncovista Innovative Therapies Inc | 2.4K | 0.0x | --- |
Netmed Inc | 140.0 | 0.0x | --- |
Health Discovery Corp | 4.1K | 0.0x | --- |
Easton Pharmaceuticals Inc | 1.3K | 0.0x | --- |
Gene Biotherapeutics Inc | 60.0 | 0.0x | --- |
Arno Therapeutics Inc | 14.8K | 0.0x | --- |
Company Information
OncoVista Innovative Therapies, Inc. is a biopharmaceutical company. The Company is engaged in developing targeted anticancer therapies by utilizing tumor-associated biomarkers. The Company's product pipeline consists of advanced (Phase II) and early (Phase I) clinical-stage compounds, late preclinical drug candidates and early preclinical leads. The Company's therapeutic strategy is based on targeting the patient's tumors with treatments that will deliver drugs selectively based upon specific biochemical characteristics of the cancer cells comprising the tumor. The Company's products include: Cordycepin (OVI-123) and L-Nucleoside Conjugates (OVI-117). Cordycepin depends upon the presence of a DNA polymerase, known as terminal deoxynucleotidyl transferase (TdT), for its therapeutic activity. OVI-117 is a thymidylate synthase (TS) inhibitor with pharmacological properties, which results in a retention of efficacy and a reduction of toxicity.
Contact Information
- Headquarters
- SUITE 104, 14785 OMICRON DRIVESAN ANTONIO, TX, United States 78245
- Phone
- 210-677-6000
- Fax
- ---
Executives
- Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer, Secretary
- Alexander Weis
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.4K |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 23.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.15 |
Book Value | $-0.26 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
